Results
PD, myopia
CONSTRICTION, CONSTRICTION, MYOPIA
In this study, one hundred and five (47.73%) children with available data were enrolled. Forty-eight subjects were in the atropine-placebo group and fifty-seven were in the placebo-atropine group. No significant difference was found between the demographic characteristics of the atropine-placebo group and the placebo-atropine group at the crossover time point (Table Demographics and characteristics at crossover time points in the atropine-placebo group and placebo-atropine group (mean ± SD)For the atropine-placebo group, 6 months after treatment cessation, the photopic PD and mesopic PD decreased significantly compared with the end of atropine treatment (3.86 ± 0.55 mm vs. 3.40 ± 0.42 mm, Biometric parameters during the follow-up period (mean ± SD)Comparison of mean change in pupil metrics of two groups after 6 months (mean ± SD)The change in pupil metrics, including photopic PD, mesopic PD, and constriction ratio, differed between the two groups (Comparison of the change in pupil metrics of the atropine-placebo group (6 months after cessation) and placebo-atropine (at cessation time point) in photopic pupil diameter (mean ± SD)
Univariable analysis and multivariable analysis of associations between myopia progression and ocular parameters in placebo-atropine groupPupil light reflex, calculated as Mesopic pupil diameter - Photopic pupil diameter; Constriction ratio, calculated as (Mesopic pupil diameter - Photopic pupil diameter) / Mesopic pupil diameter ×100%Table The univariable analysis showed that the change of AL was related to time spent on near work (